Detalhe da pesquisa
1.
Safety and efficacy of an α1 -blocker plus mirabegron compared with an α1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis.
Neurourol Urodyn
; 43(3): 604-619, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291827
2.
Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study.
Neurourol Urodyn
; 40(6): 1490-1499, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34058027
3.
What are the additional signs and symptoms in patients with detrusor underactivity and coexisting detrusor overactivity?
Neurourol Urodyn
; 37(7): 2220-2225, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29635760
4.
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patients.
Neurourol Urodyn
; 37(4): 1501-1505, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29356059
5.
Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials.
Eur Urol Focus
; 9(6): 957-965, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120417
6.
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
Clin Drug Investig
; 30(8): 489-505, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20586515
7.
Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.
Pain Pract
; 10(5): 416-27, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20602712
8.
Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
Anesth Analg
; 107(6): 2048-55, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19020157
9.
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.
Curr Med Res Opin
; 33(8): 1423-1432, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28537501
10.
Nasal function in self-reported chemically intolerant individuals.
Arch Environ Health
; 57(3): 247-54, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12507179
11.
Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Pain Physician
; 17(4): 329-43, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25054392
12.
A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.
J Opioid Manag
; 9(5): 343-56, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24353047
13.
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
Expert Opin Pharmacother
; 11(11): 1787-804, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20578811
14.
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain.
Adv Ther
; 27(6): 381-99, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20556560
15.
The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery .
Curr Med Res Opin
; 24(11): 3185-96, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18851776